title: Accelerated streptokinase and enoxaparin in ST-segment elevation acute myocardial infarction (the ASENOX study).
abstract: BACKGROUND
  The streptokinase (SK) regimen (1.5 MU/60 min) has remained unchanged in the ST-segment elevation acute myocardial infarction (STEMI) for the last 20 years.
  
  
  OBJECTIVE
  To compare the efficacy of an accelerated SK (ASK) regimen combined with enoxaparin (Enox) or heparin (UFH) with the standard SK and UFH combination in STEMI.
  
  
  METHODS
  633 consecutive patients, aged 21-74 years, admitted within 6 hours after the onset of STEMI, were divided in three groups: (1) ASKEnox (n=165): Enox 40 mg. i.v. followed by SK 1.5 MU over 20 min, either as a full dose or a double infusion of 0.75 MU over 10 min. separated by 50 min. After SK infusion, Enox was administered 1 mg/kg s.c. every 12 hours for 5-7 days; (2) ASKUFH (n=264): the same ASK regimen plus UFH 1,000 IU/h for 48-72 hours, (3) SSKUFH (n=204): SK 1.5 MU/60 min. plus UFH 1,000 IU/h for 48-72 hours. All patients received aspirin. Three coronary reperfusion (CR) criteria were used: 1. rapid cessation of chest pain; 2. rapid reduction of ST-segment elevation by more than 50% of the initial value; 3. rapid increase in plasma CK and CK-MB with a peak in the first 12 hours.
  
  
  RESULTS
  The rates of CR in the ASKEnox (77.6%) and the ASKUFH (73.5%) groups were similar but both were significantly higher than that observed in the SSKUFH group (62.2%) (p=0.002 and 0.013, respectively). The 30-day mortality rates were similar in the ASKEnox (6.06%) and the ASKUFH (6.81%) groups but both were significantly lower than in the SSKUFH group (12.74%) (p=0.048 and 0.044, respectively). SK-induced hypotension was more frequent in the ASKEnox (39.4%) and ASKUFH (38.3%) groups compared with the SSKUFH group (20.6%) (p<0.0001), but it was transient and well tolerated. Haemorrhagic stroke occurred in two patients from the SSKUFH and one patient from the ASKUFH groups.
  
  
  CONCLUSIONS
  ASKEnox and ASKUFH regimens are safe and result in a significantly higher rate of CR and a lower in-hospital mortality compared with the traditional SSKUFH regimen.
authors.affiliation: Department of Cardiology, Emergency Hospital, Bucharest, Romania. gabitatu@hotmail.com
authors.forename: Gabriel
authors.initials: G
authors.lastname: Tatu-Chitoiu
authors.forename: Cristina
authors.initials: C
authors.lastname: Teodorescu
authors.forename: Petre
authors.initials: P
authors.lastname: Capraru
authors.forename: Manuela
authors.initials: M
authors.lastname: Guran
authors.forename: Oana
authors.initials: O
authors.lastname: Istratescu
authors.forename: Monica
authors.initials: M
authors.lastname: Dan
authors.forename: Alexandrina
authors.initials: A
authors.lastname: Tatu-Chitoiu
authors.forename: Aurelia
authors.initials: A
authors.lastname: Bumbu
authors.forename: Valentin
authors.initials: V
authors.lastname: Chioncel
authors.forename: Maria
authors.initials: M
authors.lastname: Dorobantu
mesh_terms: D000328:Adult; D000368:Aged; D004334:Drug Administration Schedule; D004562:Electrocardiography; D017984:Enoxaparin / Q000008:administration & dosage*; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006329:Heart Conduction System / Q000503:physiopathology*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000503:physiopathology; D013300:Streptokinase / Q000008:administration & dosage*; D015912:Thrombolytic Therapy / Q000379:methods*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D017984:Enoxaparin; D005343:Fibrinolytic Agents; D013300:Streptokinase